Congress expands drug-detection mandate to counter emerging nitazene threat
S. 3093 — DETECT Nitazenes Act of 2025 · Filed by Eric Schmitt (R-MO) · 5 cosponsors · Introduced Nov 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Homeland Security's Science and Technology Directorate to work with the Drug Enforcement Agency to develop detection and identification technology for nitazenes—a synthetic opioid increasingly appearing in illicit drug supplies—at very low concentrations. It amends existing law to add nitazenes to the list of drugs the DHS is already tasked with detecting, alongside fentanyl and xylazine.
Why we flagged it
The bill is a straightforward expansion of existing DHS/DEA drug-detection authority to address an emerging public-health threat. It adds a newly prevalent illicit substance to an existing mandate without creating new restrictions, subsidies, or private carve-outs.
What the text implies
- Nitazenes are often mixed into heroin and counterfeit pills without user knowledge; enhanced detection may reduce accidental overdose deaths by enabling supply-chain intervention before distribution.
- The bill does not appropriate funds or specify implementation timelines, so effectiveness depends on DHS/DEA budget prioritization and technical feasibility of detecting nitazenes at 'very low concentrations'—a potentially challenging analytical threshold.
The full analysis lists 3 implications of this text.
Who stands to gain
analytical chemistry and detection-technology vendors (potential contractors to DHS/DEA for equipmen